By measuring serum levels of sCD74 and MIF in patients with heart failure or MI and in healthy subjects, researchers found that the ratio of serum sCD74/MIF was only one-tenth that of normal controls in heart failure patients, and one-fifth that of normal controls in MI patients, and that the increased sCD74/MIF ratio would enhance the depletion of myofibroblasts in infarcted scars and alleviate reactive fibrosis (43). The gene discussed is MIF; the disease is heart failure.